WO2017076308A1 - Tcr pour identifier un oligopeptide d'antigènes ny-eso-1 - Google Patents

Tcr pour identifier un oligopeptide d'antigènes ny-eso-1 Download PDF

Info

Publication number
WO2017076308A1
WO2017076308A1 PCT/CN2016/104453 CN2016104453W WO2017076308A1 WO 2017076308 A1 WO2017076308 A1 WO 2017076308A1 CN 2016104453 W CN2016104453 W CN 2016104453W WO 2017076308 A1 WO2017076308 A1 WO 2017076308A1
Authority
WO
WIPO (PCT)
Prior art keywords
tcr
seq
amino acid
variable domain
exon
Prior art date
Application number
PCT/CN2016/104453
Other languages
English (en)
Chinese (zh)
Inventor
李懿
相瑞瑞
吴万里
林燕梅
李思韵
Original Assignee
广州市香雪制药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州市香雪制药股份有限公司 filed Critical 广州市香雪制药股份有限公司
Publication of WO2017076308A1 publication Critical patent/WO2017076308A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to a TCR capable of recognizing a short peptide derived from the NY-ESO-1 antigen, and to a NY-ESO-1 specific T cell obtained by transducing the above TCR, and their prevention and treatment of NY-ESO- 1 use in related diseases.
  • NY-ESO-1 belongs to the family of Cancer-Testis Antigen (CTA). It can be expressed in testis, ovarian tissue and many different types of tumor tissues, but not in other normal tissues. It is a kind of specificity. Strong tumor antigens.
  • NY-ESO-1 is an endogenous antigen that is degraded into small molecule polypeptides after intracellular production and binds to MHC (main histocompatibility complex) molecules to form a complex that is presented to the cell surface.
  • SLLMWITQC is a short peptide derived from the NY-ESO-1 antigen and is a target for the treatment of NY-ESO-1 related diseases.
  • T cell adoptive immunotherapy is the transfer of reactive T cells specific for the target cell antigen into the patient to act on the target cells.
  • the T cell receptor (TCR) is a membrane protein on the surface of T cells that recognizes antigenic short peptides on the surface of the corresponding target cells.
  • APCs antigen presenting cells
  • pMHC complex short peptide-primary histocompatibility complex
  • TCR T cell receptor
  • the TCR comprises a TCR alpha chain variable domain and a TCR beta chain variable domain
  • the amino acid sequence of the CDR3 of the TCR alpha chain variable domain is ATDANGKII (SEQ ID NO: 12); and/or The amino acid sequence of CDR3 of the TCR ⁇ chain variable domain is ASSLGSNEQY (SEQ ID NO: 15).
  • the three complementarity determining regions (CDRs) of the TCR alpha chain variable domain are:
  • the three complementarity determining regions of the TCR ⁇ chain variable domain are:
  • the TCR comprises a TCR alpha chain variable domain and a TCR beta chain variable domain, the TCR alpha chain variable domain being an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1; Or the TCR ⁇ chain variable domain is an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 5.
  • the TCR comprises an alpha chain variable domain amino acid sequence of SEQ ID NO: 1.
  • the TCR comprises the ⁇ chain variable domain amino acid sequence of SEQ ID NO: 5.
  • the TCR is an alpha beta heterodimer comprising a TCR alpha chain constant region TRAC*01 and a TCR beta chain constant region TRBC1*01 or TRBC2*01.
  • amino acid sequence of the ⁇ chain of the TCR is SEQ ID NO: 3 and/or the ⁇ chain amino acid sequence of the TCR is SEQ ID NO: 7.
  • the TCR is soluble.
  • the TCR is single stranded.
  • the TCR is formed by linking an alpha chain variable domain to a beta chain variable domain via a peptide linker sequence.
  • the TCR is in the alpha chain variable region amino acid at the 11th, 13th, 19th, 21st, 53th, 76th, 89th, 91th or 94th position, and/or the alpha chain J gene short peptide amino acid reciprocal One or more mutations in the third position, the fifth last position or the seventh in the last number; and/or the TCRs in the ⁇ chain variable region amino acids 11, 13, 19, 21, 53, 76, 89, 91 Or the 94th, and/or ⁇ chain J gene short peptide amino acid reciprocal number 2, the last 4th or the last 6th position has one or more mutations, wherein the amino acid position number according to IMGT (International Immunogenetics Information The location number listed in the system).
  • IMGT International Immunogenetics Information
  • the alpha chain variable domain amino acid sequence of the TCR comprises SEQ ID NO: 32 and/or the beta chain variable domain amino acid sequence of the TCR comprises SEQ ID NO:34.
  • amino acid sequence of the TCR is SEQ ID NO:30.
  • the TCR comprises (a) all or part of a TCR alpha chain other than a transmembrane domain; and (b) all or part of a TCR beta chain other than a transmembrane domain;
  • cysteine residue forms an artificial disulfide bond between the alpha and beta chain constant domains of the TCR.
  • cysteine residue forming an artificial disulfide bond in the TCR replaces one or more sets of sites selected from the group consisting of:
  • the amino acid sequence of the O chain of the TCR is SEQ ID NO: 26 and/or the ⁇ chain amino acid sequence of the TCR is SEQ ID NO: 28.
  • the alpha chain variable region of the TCR and the beta chain constant region contain an artificial strand. Disulfide bond.
  • cysteine residue forming an artificial interchain disulfide bond in the TCR replaces one or more sets of sites selected from the group consisting of:
  • the TCR comprises an alpha chain variable domain and a beta chain variable domain and all or part of a beta chain constant domain other than a transmembrane domain, but which does not comprise an alpha chain constant domain, said TCR
  • the alpha chain variable domain forms a heterodimer with the beta chain.
  • the C- or N-terminus of the alpha chain and/or beta strand of the TCR incorporates a conjugate.
  • the conjugate that binds to the T cell receptor is a detectable label, a therapeutic agent, a PK modified moiety, or a combination of any of these.
  • the therapeutic agent is an anti-CD3 antibody.
  • a multivalent TCR complex comprising at least two TCR molecules, and wherein at least one TCR molecule is the TCR of the first aspect of the invention.
  • a nucleic acid molecule comprising a nucleic acid sequence encoding the TCR molecule of the first aspect of the invention or a complement thereof is provided.
  • the nucleic acid molecule comprises a nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 33 encoding a TCR alpha chain variable domain.
  • the nucleic acid molecule comprises a nucleotide sequence of SEQ ID NO: 6 or SEQ ID NO: 35 encoding a TCR ⁇ chain variable domain.
  • the nucleic acid molecule comprises the nucleotide sequence SEQ ID NO: 4 encoding the TCR alpha chain and/or comprises the nucleotide sequence SEQ ID NO: 8 encoding the TCR beta chain.
  • a vector comprising the nucleic acid molecule of the third aspect of the invention is provided; preferably, the vector is a viral vector; more preferably, the vector is slow Viral vector.
  • an isolated host cell comprising the vector of the fourth aspect of the invention or the nucleic acid molecule of the third aspect of the invention integrated with exogenous in the genome .
  • the invention provides a cell which is transduced with the nucleic acid molecule of the third aspect of the invention or the vector of the fourth aspect of the invention; preferably, the cell is a T cell or a stem cell .
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier, a TCR according to the first aspect of the present invention, a TCR complex according to the second aspect of the present invention, and a present invention are provided.
  • the nucleic acid molecule of the third aspect of the invention, the vector of the fourth aspect of the invention, or the sixth aspect of the invention The cells described in the aspects.
  • the T cell receptor of the first aspect of the invention, or the TCR complex of the second aspect of the invention, the nucleic acid molecule of the third aspect of the invention, the fourth aspect of the invention The use of the vector of the aspect, or the cell of the sixth aspect of the invention, for the manufacture of a medicament for the treatment of a tumor or an autoimmune disease.
  • a method of treating a disease comprising administering an appropriate amount of the T cell receptor of the first aspect of the invention, or the TCR complex of the second aspect of the invention to a subject in need of treatment
  • the nucleic acid molecule of the third aspect of the invention, the vector of the fourth aspect of the invention, or the cell of the sixth aspect of the invention, or the pharmaceutical composition of the seventh aspect of the invention comprising administering an appropriate amount of the T cell receptor of the first aspect of the invention, or the TCR complex of the second aspect of the invention to a subject in need of treatment.
  • the disease is a tumor
  • the tumor comprises neuroblastoma, sarcoma, melanoma, prostate cancer, bladder cancer, breast cancer, multiple myeloma, hepatocellular carcinoma, oral squamous cell carcinoma, esophageal cancer And gastric cancer, lung cancer, head and neck squamous cell carcinoma, colon cancer, ovarian cancer and the like.
  • Figure 1a, Figure 1b, Figure 1c, Figure 1d, Figure 1e and Figure 1f are the TCR alpha chain variable domain amino acid sequence, the TCR alpha chain variable domain nucleotide sequence, the TCR alpha chain amino acid sequence, the TCR alpha chain nucleotide sequence, respectively.
  • 2a, 2b, 2c, 2d, 2e, and 2f are a TCR ⁇ chain variable domain amino acid sequence, a TCR ⁇ chain variable domain nucleotide sequence, a TCR ⁇ chain amino acid sequence, a TCR ⁇ chain nucleotide sequence, respectively.
  • Figure 3 shows the results of double positive staining of CD8 + and tetramer-PE in monoclonal cells.
  • Figures 4a and 4b are the amino acid sequence and nucleotide sequence of the soluble TCR alpha chain, respectively.
  • Figures 5a and 5b are the amino acid sequence and nucleotide sequence of the soluble TCR ⁇ chain, respectively.
  • Figure 6 is a gel diagram of the soluble TCR obtained after purification.
  • the leftmost lane is the reducing gel
  • the middle lane is the molecular weight marker
  • the rightmost lane is the non-reducing gel.
  • Figures 7a and 7b are the amino acid sequence and nucleotide sequence of a single-chain TCR, respectively.
  • Figures 8a and 8b are the amino acid sequence and nucleotide sequence, respectively, of a single-chain TCR alpha chain.
  • Figures 9a and 9b are the amino acid sequence and nucleotide sequence of a single-chain TCR ⁇ chain, respectively.
  • Figures 10a and 10b are the amino acid sequence and nucleotide sequence, respectively, of a single-chain TCR linker.
  • Figure 11 is a gel diagram of the soluble single-chain TCR obtained after purification.
  • Figure 12 is a BIAcore kinetic map of the soluble TCR of the present invention in combination with the SLLMWITQC-HLA A0201 complex.
  • Figure 13 is a BIAcore kinetic map of the soluble single chain TCR of the present invention in combination with the SLLMWITQC--HLA A0201 complex.
  • Figure 14 shows that cells transducing the TCR of the present invention have a killing effect on target cells expressing the relevant antigen, but have substantially no killing effect on target cells that do not express the relevant antigen.
  • the inventors have found extensively and intensively, and found a TCR capable of specifically binding to the NY-ESO-1 antigen short peptide SLLMWITQC (SEQ ID NO: 9), which forms a complex with HLA A0201 and They are presented together to the cell surface.
  • the invention also provides a nucleic acid fragment encoding the TCR And a vector comprising the nucleic acid molecule.
  • the invention also provides cells that transduce the TCR of the invention.
  • the MHC molecule is a protein of the immunoglobulin superfamily and may be a class I or class II MHC molecule. Therefore, it is specific for the presentation of antigens, and different individuals have different MHCs that can present different short peptides of a protein antigen to the surface of the respective APC cells.
  • Human MHC is commonly referred to as the HLA gene or the HLA complex.
  • T cell receptor is the only receptor that presents a specific antigenic peptide on the major histocompatibility complex (MHC).
  • MHC major histocompatibility complex
  • APC antigen presenting cells
  • TCR is a glycoprotein on the surface of a cell membrane in the form of a heterodimer formed by an alpha chain/beta chain or a gamma chain/delta chain.
  • the TCR heterodimer consists of alpha and beta chains in 95% of T cells, while 5% of T cells have a TCR consisting of gamma and delta chains.
  • the native ⁇ heterodimeric TCR has an ⁇ chain and a ⁇ chain, and the ⁇ chain and the ⁇ chain constitute a subunit of the ⁇ heterodimeric TCR.
  • each of the alpha and beta chains comprises a variable region, a junction region, and a constant region
  • the beta chain typically also contains a short polymorphic region between the variable region and the junction region, but the polymorphic region is often considered as a junction region. a part of.
  • Each variable region comprises three CDRs (complementarity determining regions), CDR1, CDR2 and CDR3, which are chimeric in framework regions.
  • the CDR regions determine the binding of the TCR to the pMHC complex, wherein the CDR3 is recombined from the variable region and the junction region and is referred to as the hypervariable region.
  • the alpha and beta chains of TCR are generally considered to have two "domains", namely a variable domain and a constant domain, and the variable domain consists of linked variable and linking regions.
  • the sequence of the TCR constant domain can be found in the public database of the International Immunogenetics Information System (IMGT).
  • IMGT International Immunogenetics Information System
  • the constant domain sequence of the TCR molecule ⁇ chain is “TRAC*01”
  • the constant domain sequence of the TCR molecule ⁇ chain is “TRBC1*”. 01" or "TRBC2*01”.
  • the alpha and beta chains of TCR also contain a transmembrane and cytoplasmic regions with a short cytoplasmic region.
  • polypeptide of the present invention TCR of the present invention
  • T cell receptor of the present invention T cell receptor of the present invention
  • the position numbers of the amino acid sequences of TROC*01 and TRBC1*01 or TRBC2*01 are numbered in order from N-terminus to C-terminus, such as TRBC1*01 or TRBC2*01.
  • the 60th amino acid is P (valine), which may be described as Pro60 of TRBC1*01 or TRBC2*01 exon 1 in the present invention, or may be It is expressed as the 60th amino acid of exon 1 of TRBC1*01 or TRBC2*01, and in the case of TRBC1*01 or TRBC2*01, the 61st amino acid is Q in the order from N to C.
  • Amide which may be described as Gln61 of TRBC1*01 or TRBC2*01 exon 1 in the present invention, or may be expressed as amino acid 61 of exon 1 of TRBC1*01 or TRBC2*01, other And so on.
  • the position numbers of the amino acid sequences of the variable regions TRAV and TRBV are numbered according to the positions listed in the IMGT.
  • the position number listed in IMGT is 46, which is described in the present invention as amino acid 46 of TRAV, and so on.
  • special instructions will be given.
  • a first aspect of the invention provides a TCR molecule capable of binding to the SLLMWITQC-HLA A0201 complex.
  • the TCR molecule is isolated or purified.
  • the alpha and beta strands of the TCR each have three complementarity determining regions (CDRs).
  • the alpha chain of the TCR comprises a CDR having the following amino acid sequence:
  • the three complementarity determining regions of the TCR ⁇ chain variable domain are:
  • the chimeric TCR can be prepared by embedding the above-described CDR region amino acid sequences of the present invention into any suitable framework structure.
  • the framework structure is compatible with the CDR regions of the TCRs of the present invention, one skilled in the art can design or synthesize TCR molecules having corresponding functions in accordance with the CDR regions disclosed herein.
  • a TCR molecule of the invention refers to a TCR molecule comprising the above-described alpha and/or beta chain CDR region sequences and any suitable framework structure.
  • the TCR alpha chain variable domain of the invention is an amino acid sequence having at least 90%, preferably 95%, more preferably 98% sequence identity to SEQ ID NO: 1; and/or the TCR ⁇ chain variable domain of the invention is SEQ ID NO: 5 has an amino acid sequence of at least 90%, preferably 95%, more preferably 98% sequence identity.
  • the TCR molecule of the invention is a heterodimer composed of alpha and beta chains.
  • the alpha chain of the heterodimeric TCR molecule comprises a variable domain and a constant domain, the alpha chain variable domain amino acid sequence comprising the CDR1 (SEQ ID NO: 10), CDR2 (SEQ) ID NO: 11) and CDR3 (SEQ ID NO: 12).
  • the TCR molecule comprises an alpha chain variable domain amino acid sequence of SEQ ID NO: 1. More preferably, the alpha chain variable domain amino acid sequence of the TCR molecule is SEQ ID NO: 1.
  • the beta strand of the heterodimeric TCR molecule comprises a variable domain and a constant domain, the beta strand variable domain amino acid sequence comprising the CDR1 (SEQ ID NO: 13), CDR2 (SEQ ID) NO: 14) and CDR3 (SEQ ID NO: 15).
  • the TCR molecule comprises a beta chain variable domain amino acid sequence of SEQ ID NO:5. More preferably, the beta strand variable domain amino acid sequence of the TCR molecule is SEQ ID NO:5.
  • the TCR molecule of the invention is a single-chain TCR molecule consisting of part or all of the alpha chain and/or part or all of the beta chain.
  • a description of single-chain TCR molecules can be found in Chung et al (1994) Proc. Natl. Acad. Sci. USA 91, 12654-12658.
  • One skilled in the art can readily construct single-chain TCR molecules comprising the CDRs regions of the invention, as described in the literature.
  • the single-chain TCR molecule comprises V ⁇ , V ⁇ and C ⁇ , preferably linked in order from N-terminus to C-terminus.
  • the alpha chain variable domain amino acid sequence of the single chain TCR molecule comprises CDR1 (SEQ ID NO: 10), CDR2 (SEQ ID NO: 11) and CDR3 (SEQ ID NO: 12) of the above alpha chain.
  • the single-chain TCR molecule comprises an alpha chain variable domain amino acid sequence of SEQ ID NO: 1. More preferably, the alpha chain variable domain amino acid sequence of the single chain TCR molecule is SEQ ID NO: 1.
  • the ⁇ chain variable domain amino acid sequence of the single-chain TCR molecule comprises CDR1 (SEQ ID NO: 13), CDR2 (SEQ ID NO: 14) and CDR3 (SEQ ID NO: 15) of the above-described ⁇ chain.
  • the single-chain TCR molecule comprises the ⁇ -chain variable domain amino acid sequence of SEQ ID NO: 5. More preferably, the ⁇ chain variable domain amino acid of the single-chain TCR molecule The sequence is SEQ ID NO:5.
  • the constant domain of the TCR molecule of the invention is a human constant domain.
  • the constant domain sequence of the ⁇ chain of the TCR molecule of the present invention may be "TRAC*01”
  • the constant domain sequence of the ⁇ chain of the TCR molecule may be "TRBC1*01” or "TRBC2*01”.
  • the 53rd position of the amino acid sequence given in TRAC*01 of IMGT is Arg, which is represented here as: Arg53 of exon 1 of TRAC*01, and so on.
  • the amino acid sequence of the ⁇ chain of the TCR molecule of the present invention is SEQ ID NO: 3, and/or the amino acid sequence of the ⁇ chain is SEQ ID NO: 7.
  • TCR The naturally occurring TCR is a membrane protein that is stabilized by its transmembrane domain.
  • TCR can also be developed for diagnosis and treatment, when soluble TCR molecules are required. Soluble TCR molecules do not include their transmembrane regions. Soluble TCR has a wide range of uses, not only for studying the interaction of TCR with pMHC, but also as a diagnostic tool for detecting infection or as a marker for autoimmune diseases.
  • soluble TCR can be used to deliver therapeutic agents (such as cytotoxic compounds or immunostimulatory compounds) to cells that present specific antigens.
  • soluble TCRs can also bind to other molecules (eg, anti-CD3 antibodies). To redirect T cells so that they target cells that present a particular antigen.
  • the present invention also obtains a soluble TCR specific for the NY-ESO-1 antigen short peptide.
  • the TCR of the invention can be a TCR that introduces an artificial disulfide bond between the residues of its alpha and beta chain constant domains.
  • the cysteine residue forms an artificial interchain disulfide bond between the alpha and beta chain constant domains of the TCR.
  • a cysteine residue can replace other amino acid residues at a suitable position in the native TCR to form an artificial interchain disulfide bond. For example, a Thr248 residue of the exon 1 of TRAC*01 and a cysteine residue of Ser57 of the exon 1 of TRBC1*01 or TRBC2*01 are substituted to form a disulfide bond.
  • Other sites for introducing a cysteine residue to form a disulfide bond may also be: Thr45 of TRAC*01 exon 1 and Ser77 of TRBC1*01 or TRBC2*01 exon 1; TRAC*01 exon 1 of Tyr10 and TRBC1*01 or TRBC2*01 exon 1 of Ser17; TRAC*01 exon 1 of Thr45 and TRBC1*01 or TRBC2*01 exon 1 of Asp59; TRAC*01 exon 1 Ser15 and TRBC1*01 or TRBC2*01 exon 1 of Glu15; TRAC*01 exon 1 of Arg53 and TRBC1*01 or TRBC2*01 exon 1 of Ser54; TRAC*01 exon 1 of Pro89 and ABC19 of exon 1 of TRBC1*01 or TRBC2*01; or Tyr10 and TRBC1*01 of exon 1 of TRAC*01 or Glu20 of exon 1 of TRBC2*01.
  • a cysteine residue replaces any of the above-mentioned sites in the ⁇ and ⁇ chain constant domains.
  • a maximum of 50, or a maximum of 30, or a maximum of 15, or a maximum of 10, or a maximum of 8 or fewer amino acids may be truncated at one or more C-termini of the TCR constant domains of the invention such that they are not included
  • the cysteine residue is used for the purpose of deleting the natural disulfide bond, and the above object can also be achieved by mutating the cysteine residue forming the natural disulfide bond to another amino acid.
  • the TCR of the present invention may comprise an artificial disulfide bond introduced between residues of its ⁇ and ⁇ chain constant domains.
  • the constant domains may or may not contain the introduced artificial disulfide bonds as described above, and the TCRs of the present invention may each contain a TRAC constant domain sequence and a TRBC1 or TRBC2 constant domain sequence.
  • the TRAC constant domain sequence of TCR and the TRBC1 or TRBC2 constant domain sequence can be joined by a native disulfide bond present in the TCR.
  • the TCR of the present invention further comprises a TCR having a mutation in its hydrophobic core region, and the mutation of these hydrophobic core regions is preferably a mutation capable of improving the stability of the soluble TCR of the present invention, as in the publication number It is described in the patent document of WO2014/206304.
  • Such a TCR can be mutated at its position in the following variable domain hydrophobic core: (alpha and/or beta chain) variable region amino acids 11, 13, 19, 21, 53, 76, 89, 91, 94, and / Or the ⁇ -chain J gene (TRAJ) short peptide amino acid position reciprocal position 3, 5, 7 and/or ⁇ chain J gene (TRBJ) short peptide amino acid position reciprocal position 2, 4, 6 where the amino acid sequence position number Locations listed in the International Immunogenetics Information System (IMGT) Numbering.
  • IMGT International Immunogenetics Information System
  • the TCR in which the hydrophobic core region is mutated in the present invention may be a stable soluble single-chain TCR composed of a flexible peptide chain linking the variable domains of the ⁇ and ⁇ chains of the TCR.
  • the flexible peptide chain of the present invention may be any peptide chain suitable for linking the TCR alpha and beta chain variable domains.
  • the single-chain soluble TCR constructed in Example 4 of the present invention has the ⁇ chain variable domain amino acid sequence of SEQ ID NO: 32, the encoded nucleotide sequence of SEQ ID NO: 33, and the ⁇ chain variable domain amino acid sequence.
  • SEQ ID NO: 34 the nucleotide sequence encoded is SEQ ID NO:35.
  • Patent Document 201510260322.4 also discloses that introduction of an artificial interchain disulfide bond between the ⁇ chain variable region of the TCR and the ⁇ chain constant region can significantly improve the stability of the TCR. Therefore, the ⁇ chain variable region of the high affinity TCR of the present invention and the ⁇ chain constant region may further contain an artificial interchain disulfide bond.
  • cysteine residue forming an artificial interchain disulfide bond between the ⁇ chain variable region of the TCR and the ⁇ chain constant region is substituted with: amino acid 46 of TRAV and TRBC1*01 or TRBC2* 01 amino acid at position 60 of exon 1; amino acid at position 47 of TRAV and amino acid at position 61 of exon 1 of TRBC1*01 or TRBC2*01; amino acid at position 46 of TRAV and TRBC1*01 or TRBC2*01 The amino acid at position 61 of the 1st; or the amino acid at position 47 of TRAV and the amino acid at position 60 of exon 1 of TRBC1*01 or TRBC2*01.
  • such a TCR may comprise (i) all or part of a TCR alpha chain other than its transmembrane domain, and (ii) all or part of a TCR beta chain other than its transmembrane domain, wherein (i) and (ii) Both comprise a variable domain of the TCR chain and at least a portion of the constant domain, the alpha chain forming a heterodimer with the beta chain. More preferably, such a TCR may comprise an alpha chain variable domain and a beta chain variable domain and all or part of a beta chain constant domain other than a transmembrane domain, but which does not comprise an alpha chain constant domain, said TCR alpha The chain variable domain forms a heterodimer with the beta chain.
  • the TCR of the present invention can also be provided in the form of a multivalent complex.
  • the multivalent TCR complex of the present invention comprises a polymer formed by combining two, three, four or more TCRs of the present invention, such as a tetrameric domain of p53 to produce a tetramer, or more A complex formed by combining a TCR of the invention with another molecule.
  • the TCR complexes of the invention can be used to track or target cells that present a particular antigen in vitro or in vivo, as well as intermediates that produce other multivalent TCR complexes for such applications.
  • the TCR of the present invention may be used singly or in combination with the conjugate in a covalent or other manner, preferably in a covalent manner.
  • the conjugate comprises a detectable label (for diagnostic purposes, wherein the TCR is used to detect the presence of a cell presenting the SLLMWITQC-HLA A0201 complex), a therapeutic agent, a PK (protein kinase) modified moiety or any of these substances The combination is combined or coupled.
  • Detectable labels for diagnostic purposes include, but are not limited to, fluorescent or luminescent labels, radioactive labels, MRI (magnetic resonance imaging) or CT (electron computed tomography) contrast agents, or capable of producing detectable products Enzyme.
  • Therapeutic agents that can be combined or coupled to the TCRs of the invention include, but are not limited to: 1. Radionuclides (Koppe et al, 2005, Cancer metastasis reviews 24, 539); 2. Biotoxicity (Chaudhary et al, 1989) , Nature 339, 394; Epel et al, 2002, Cancer Immunology and Immunotherapy 51, 565); 3. Cytokines such as IL-2, etc.
  • Liposomes (Mamot et al., 2005, Cancer research 65, 11631); 9. Nanomagnetic particles; 10. Prodrug activating enzymes (eg, DT-diaphorase) DTD) or biphenyl hydrolase-like protein (BPHL); 11. chemotherapeutic agent (eg, cisplatin) or any form of nanoparticles, and the like.
  • Prodrug activating enzymes eg, DT-diaphorase
  • BPHL biphenyl hydrolase-like protein
  • chemotherapeutic agent eg, cisplatin
  • the TCR of the invention may also be a hybrid TCR comprising sequences derived from more than one species.
  • the TCR of the invention may comprise a human variable domain and a murine constant domain.
  • a drawback of this approach is that it may trigger an immune response. Therefore, there should be a regulatory regimen for immunosuppression when used in adoptive T cell therapy to allow for the implantation of murine T cells.
  • amino acid names in this article are represented by the international single letter or three English letters.
  • the correspondence between the single English letters of the amino acid name and the three English letters is as follows: Ala (A), Arg (R), Asn (N), Asp (D), Cys (C), Gln (Q), Glu (E), Gly (G), His (H), Ile (I), Leu (L), Lys (K), Met (M), Phe (F), Pro (P), Ser (S), Thr (T), Trp (W), Tyr (Y), Val (V).
  • a second aspect of the invention provides a nucleic acid molecule encoding a TCR molecule of the first aspect of the invention, or a portion thereof, which may be one or more CDRs, a variable domain of an alpha and/or beta chain, and an alpha chain and/or Or beta chain.
  • nucleotide sequence encoding the CDR region of the alpha chain of the TCR molecule of the first aspect of the invention is as follows:
  • nucleotide sequence encoding the CDR region of the ⁇ chain of the TCR molecule of the first aspect of the invention is as follows:
  • nucleotide sequence of a nucleic acid molecule of the invention encoding a TCR alpha chain of the invention comprises SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18, and/or a nucleic acid molecule of the invention encoding a TCR ⁇ chain of the invention
  • the nucleotide sequence includes SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21.
  • the nucleotide sequence of the nucleic acid molecule of the present invention may be single-stranded or double-stranded, and the nucleic acid molecule may be RNA or DNA, and may or may not contain an intron.
  • the nucleotide sequence of the nucleic acid molecule of the invention does not comprise an intron but is capable of encoding a polypeptide of the invention, for example, the nucleotide sequence of a nucleic acid molecule of the invention encoding a TCR alpha chain variable domain of the invention comprises SEQ ID NO: 2 and / or the nucleotide sequence of the nucleic acid molecule of the invention encoding a TCR beta chain variable domain of the invention comprises SEQ ID NO: 6.
  • the nucleotide sequence of a nucleic acid molecule of the invention encoding a TCR alpha chain variable domain of the invention comprises SEQ ID NO: 33 and/or the nucleotide sequence of a nucleic acid molecule of the invention encoding a TCR beta chain variable domain of the invention comprising the SEQ ID NO: 35. More preferably, the nucleotide sequence of the nucleic acid molecule of the invention comprises SEQ ID NO: 4 and/or SEQ ID NO: 8. Alternatively, the nucleotide sequence of the nucleic acid molecule of the invention is SEQ ID NO:31.
  • nucleic acid sequence encoding a TCR of the invention may be the same or a degenerate variant of the nucleic acid sequence set forth in the Figures of the invention.
  • a "degenerate variant” refers to a nucleic acid sequence which encodes a protein sequence having SEQ ID NO: 1, but differs from the sequence of SEQ ID NO: 2.
  • the nucleotide sequence can be codon optimized. Different cells are different in the utilization of specific codons, and the number of expressions can be increased by changing the codons in the sequence depending on the type of the cell. Codon selection tables for mammalian cells as well as a variety of other organisms are well known to those skilled in the art.
  • the full length sequence of the nucleic acid molecule of the present invention or a fragment thereof can generally be used, but not limited to, PCR amplification method, heavy Obtained by group method or synthetic method.
  • PCR amplification method heavy Obtained by group method or synthetic method.
  • the DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art.
  • the DNA can be a coding strand or a non-coding strand.
  • the invention also relates to vectors comprising the nucleic acid molecules of the invention, including expression vectors, ie, constructs that are capable of expression in vivo or in vitro.
  • expression vectors include bacterial plasmids, bacteriophages, and animal and plant viruses.
  • Viral delivery systems include, but are not limited to, adenoviral vectors, adeno-associated virus (AAV) vectors, herpesvirus vectors, retroviral vectors, lentiviral vectors, baculovirus vectors.
  • AAV adeno-associated virus
  • the vector can transfer a nucleotide of the invention into a cell, such as a T cell, such that the cell expresses a TCR specific for the NY-ESO-1 antigen.
  • a cell such as a T cell
  • the vector should be capable of sustained high levels of expression in T cells.
  • the invention also relates to host cells genetically engineered using the vectors or coding sequences of the invention.
  • the host cell contains the vector of the present invention or a nucleic acid molecule of the present invention in which the chromosome is integrated.
  • the host cell is selected from the group consisting of prokaryotic cells and eukaryotic cells, such as E. coli, yeast cells, CHO cells, and the like.
  • the invention also encompasses isolated cells, particularly T cells, which express the TCR of the invention.
  • the T cell can be derived from a T cell isolated from the subject, or can be a mixed cell population isolated from the subject, such as a portion of a peripheral blood lymphocyte (PBL) population.
  • PBL peripheral blood lymphocyte
  • the cells can be isolated from peripheral blood mononuclear cells (PBMC), which can be CD4 + helper T cells or CD8 + cytotoxic T cells.
  • PBMC peripheral blood mononuclear cells
  • the cells can be in a mixed population of CD4 + helper T cells/CD8 + cytotoxic T cells.
  • the cells can be activated with antibodies (e.g., anti-CD3 or anti-CD28 antibodies) to enable them to be more readily transfected, e.g., with a vector comprising a nucleotide sequence encoding a TCR molecule of the invention. dye.
  • antibodies e.g., anti-CD3 or anti-CD28 antibodies
  • the cells of the invention may also be or be derived from stem cells, such as hematopoietic stem cells (HSCs). Transfer of the gene to HSC does not result in the expression of TCR on the cell surface because the stem cell surface does not express CD3 molecules. However, when stem cells differentiate into lymphoid precursors that migrate to the thymus, expression of the CD3 molecule will initiate expression of the introduced TCR molecule on the surface of thymocytes.
  • stem cells differentiate into lymphoid precursors that migrate to the thymus
  • CD3 molecule will initiate expression of the introduced TCR molecule on the surface of thymocytes.
  • T cell transfection with DNA or RNA encoding the TCR of the invention e.g., Robbins et al., (2008) J. Immunol. 180: 6116-6131.
  • T cells expressing the TCR of the present invention can be used in adoptive immunotherapy.
  • Those skilled in the art will be aware of many suitable methods for performing adoptive therapy (e.g., Rosenberg et al., (2008) Nat Rev Cancer 8(4): 299-308).
  • the invention also relates to a method of treating and/or preventing a NY-ESO-1 related disease in a subject comprising the step of adoptively transferring NY-ESO-1 specific T cells to the subject.
  • the NY-ESO-1 specific T cell recognizes the SLLMWITQC-HLA A0201 complex.
  • the NY-ESO-1 specific T cells of the invention can be used to treat any NY-ESO-1 related diseases presenting the NY-ESO-1 antigen short peptide SLLMWITQC-HLA A0201 complex, including but not limited to tumors, preferably Tumors include neuroblastoma, sarcoma, melanoma, prostate cancer, bladder cancer, breast cancer, multiple myeloma, hepatocellular carcinoma, oral squamous cell carcinoma, esophageal cancer, and gastric cancer, lung cancer, head and neck squamous cell carcinoma, Colon cancer, ovarian cancer, etc.
  • Tumors include neuroblastoma, sarcoma, melanoma, prostate cancer, bladder cancer, breast cancer, multiple myeloma, hepatocellular carcinoma, oral squamous cell carcinoma, esophageal cancer, and gastric cancer, lung cancer, head and neck squamous cell carcinoma, Colon cancer, ovarian cancer, etc.
  • the T cells of a patient or a volunteer having a disease associated with the NY-ESO-1 antigen can be isolated, and the TCR of the present invention can be introduced into the above T cells, and then these genetically engineered cells can be returned to the patient. treatment.
  • the present invention provides a method for treating NY-ESO-1 related diseases. The method comprises separating an isolated T cell expressing a TCR of the invention, preferably, the T cell is derived from the patient itself and is administered to the patient.
  • it comprises (1) isolating a patient's T cells, (2) transducing T cells in vitro with a nucleic acid molecule of the invention or a nucleic acid molecule capable of encoding the TCR molecule of the invention, and (3) inputting genetically engineered T cells into the patient in vivo.
  • the number of cells that are isolated, transfected, and returned can be determined by the physician.
  • the TCR of the present invention can bind to the NY-ESO-1 antigen short peptide complex SLLMWITQC-HLA A0201, and the cells transduced with the TCR of the present invention can be specifically activated and have a strong killing effect on target cells.
  • Peripheral blood lymphocytes from healthy volunteers with genotype HLA-A0201 were stimulated with synthetic short peptide SLLMWITQC (SEQ ID NO.: 9; Beijing Cypress Biotech Co., Ltd.).
  • SLLMWITQC short peptide was renatured with biotinylated HLA-A0201 to prepare a pHLA haploid.
  • haploids were combined with PE-labeled streptavidin (BD) into PE-labeled tetramers, and the tetramer and anti-CD8-APC double positive cells were sorted.
  • the sorted cells were expanded and subjected to secondary sorting as described above, followed by monoclonalization by limiting dilution. Monoclonal cells were stained with tetramers and the double positive clones screened are shown in Figure 3.
  • Example 1 Screening of short peptides to antigen SLLMWITQC-specific, HLA-A0201 restricted T cell clones Total RNA.
  • the cDNA was synthesized using clontech's SMART RACE cDNA Amplification Kit, and the primers were designed to be conserved in the C-terminal region of the human TCR gene.
  • the sequence was cloned into a T vector (TAKARA) for sequencing. It should be noted that this sequence is a complementary sequence and does not contain introns. After sequencing, the ⁇ chain and ⁇ chain sequence structures of the TCR expressed by the double positive clone are shown in FIG. 1 and FIG. 2 respectively, and FIG.
  • FIG. 1a, FIG. 1b, FIG. 1c, FIG. 1d, FIG. 1e and FIG. 1f are respectively TCR ⁇ chains.
  • Figure 2b, Figure 2c, Figure 2d, Figure 2e and Figure 2f are the TCR ⁇ chain variable domain amino acid sequence, the TCR ⁇ chain variable domain nucleotide sequence, the TCR ⁇ chain amino acid sequence, the TCR ⁇ chain nucleotide sequence, and the leader sequence, respectively.
  • the alpha chain has been identified to comprise a CDR having the following amino acid sequence:
  • the beta strand comprises a CDR having the following amino acid sequence:
  • the full-length genes of the TCR alpha chain and the beta chain were cloned into the lentiviral expression vector pLenti (addgene) by overlap PCR, respectively.
  • the TCR ⁇ -2A-TCR ⁇ fragment was obtained by ligating the full-length genes of the TCR ⁇ chain and the TCR ⁇ chain by overlap PCR.
  • the lentiviral expression vector and TCR ⁇ -2A-TCR ⁇ were digested to obtain a pLenti-TRA-2A-TRB-IRES-NGFR plasmid.
  • a lentiviral vector pLenti-eGFP expressing eGFP was also constructed. The 1981T/17 is then used to package the pseudovirus.
  • the ⁇ and ⁇ chains of the TCR molecule of the present invention may comprise only their variable domains and partial constant domains, respectively, and a cysteine residue is introduced in the constant domains of the ⁇ and ⁇ chains, respectively.
  • the positions at which cysteine residues are introduced are Thr48 of exon 1 of TRAC*01 and Ser57 of exon 1 of TRBC2*01, respectively; amino acid sequence and nucleotide of ⁇ chain thereof
  • the sequences are shown in Figures 4a and 4b, respectively, and the amino acid sequence and nucleotide sequence of the ⁇ chain are shown in Figures 5a and 5b, respectively, and the introduced cysteine residues are indicated by bold and underlined letters.
  • the above TCR ⁇ and ⁇ chain target gene sequences were synthesized and inserted into the expression vector pET28a+ (Novagene) by standard methods described in the Molecular Cloning a Laboratory Manual (3rd edition, Sambrook and Russell). ), the upstream and downstream cloning sites are NcoI and NotI, respectively. The insert was sequenced to confirm that it was correct.
  • TCR ⁇ and ⁇ chain were transformed into expression plasmid BL21(DE3) by chemical transformation, respectively, and the bacteria were grown in LB medium.
  • the resulting inclusion bodies were extracted by BugBuster Mix (Novagene) and washed repeatedly with BugBuster solution.
  • the inclusion bodies were finally dissolved in 6 M guanidine hydrochloride, 10 mM dithiothreitol (DTT), 10 mM ethylenediaminetetraacetic acid (EDTA). ), in 20 mM Tris (pH 8.1).
  • the dissolved TCR ⁇ and ⁇ chains were rapidly mixed in 5 M urea, 0.4 M arginine, 20 mM Tris (pH 8.1), 3.7 mM cystamine, 6.6 mM ⁇ -mercapoethylamine (4 ° C) at a final concentration of 1:1. 60 mg/mL. After mixing, the solution was dialyzed against 10 volumes of deionized water (4 ° C), and after 12 hours, deionized water was exchanged for buffer (20 mM Tris, pH 8.0) and dialysis was continued at 4 ° C for 12 hours.
  • the solution after completion of dialysis was filtered through a 0.45 ⁇ M filter, and then purified by an anion exchange column (HiTrap Q HP, 5 ml, GE Healthcare).
  • the TCR containing the refolding successful alpha and beta dimers was confirmed by SDS-PAGE gel.
  • the TCR was then further purified by gel filtration chromatography (HiPrep 16/60, Sephacryl S-100HR, GE Healthcare).
  • the purified TCR purity was determined by SDS-PAGE to be greater than 90%, and the concentration was determined by the BCA method.
  • the SDS-PAGE gel of the soluble TCR obtained by the present invention is shown in Fig. 6.
  • variable domains of TCR ⁇ and ⁇ -chain in Example 2 were constructed as a stable soluble single-chain TCR molecule linked by a flexible short linker using the method of site-directed mutagenesis as described in the patent document WO2014/206304.
  • the amino acid sequence and nucleotide sequence of the single-chain TCR molecule are shown in Figures 7a and 7b, respectively.
  • the amino acid sequence and nucleotide sequence of the ⁇ chain variable domain are shown in Figure 8a and Figure 8b, respectively; the amino acid sequence and nucleotide sequence of the ⁇ chain variable domain are shown in Figure 9a and Figure 9b, respectively;
  • the amino acid sequence and nucleotide sequence of the sequence are shown in Figures 10a and 10b, respectively.
  • the gene of interest was digested with NcoI and NotI and ligated with the pET28a vector digested with NcoI and NotI.
  • the ligation product was transformed into E. coli DH5 ⁇ , coated with kanamycin-containing LB plate, inverted culture at 37 ° C overnight, and the positive clones were picked for PCR screening.
  • the positive recombinants were sequenced to determine the correct sequence and the recombinant plasmid was extracted.
  • E. coli BL21 (DE3) for expression.
  • the BL21(DE 3) colonies containing the recombinant plasmid pET28a-template strand prepared in Example 4 were all inoculated into LB medium containing kanamycin, cultured at 37 ° C until the OD600 was 0.6-0.8, and IPTG was added to the final concentration. The culture was continued at 37 ° C for 4 h at 0.5 mM.
  • the cell pellet was harvested by centrifugation at 5000 rpm for 15 min, the cell pellet was lysed with Bugbuster Master Mix (Merck), the inclusion bodies were recovered by centrifugation at 6000 rpm for 15 min, and then washed with Bugbuster (Merck) to remove cell debris and membrane fraction, centrifuged at 6000 rpm for 15 min, and collected. body.
  • the inclusion body was dissolved in a buffer (20 mM Tris-HCl pH 8.0, 8 M urea), and the insoluble matter was removed by high-speed centrifugation. The supernatant was fractionated by the BCA method, and then stored at -80 ° C until use.
  • the reconstituted solution was placed in a cellulose membrane dialysis bag with a cut-off amount of 4 kDa, and the dialysis bag was placed in 1 L of pre-cooled water and slowly stirred at 4 ° C overnight. After 17 hours, the dialysate was changed to 1 L of pre-cooled buffer (20 mM Tris-HCl pH 8.0), dialysis was continued for 8 h at 4 ° C, and the dialysate was replaced with the same fresh buffer to continue dialysis overnight.
  • pre-cooled buffer 20 mM Tris-HCl pH 8.0
  • the sample was filtered through a 0.45 ⁇ m filter, and the protein was purified by vacuum degassing through an anion exchange column (HiTrap Q HP, GE Healthcare) in a linear gradient of 0-mM NaCl prepared with 20 mM Tris-HCl pH 8.0.
  • the collected fractions were subjected to SDS-PAGE analysis, and the fractions containing the single-chain TCR were concentrated and further purified by a gel filtration column (Superdex 7510/300, GE Healthcare), and the target components were also subjected to SDS-PAGE analysis.
  • the eluted fraction for BIAcore analysis was further tested for purity using gel filtration.
  • the conditions were as follows: column Agilent Bio SEC-3 (300A, ⁇ 7.8 ⁇ 300 mm), mobile phase 150 mM phosphate buffer, flow rate 0.5 mL/min, column temperature 25 ° C, UV detection wavelength 214 nm.
  • the binding activity of the TCR molecule obtained in Example 3 and Example 5 to the SLLMWITQC-HLA A0201 complex was examined using a BIAcore T200 real-time analysis system.
  • the anti-streptavidin antibody (GenScript) was added to a coupling buffer (10 mM sodium acetate buffer, pH 4.77), and then the antibody was passed through a CM5 chip previously activated with EDC and NHS to immobilize the antibody on the surface of the chip. Finally, the unreacted activated surface was blocked with a solution of ethanolamine in hydrochloric acid to complete the coupling process at a coupling level of about 15,000 RU.
  • a low concentration of streptavidin is passed over the surface of the coated antibody chip, then the SLLMWITQC-HLA A0201 complex is flowed through the detection channel, the other channel is used as a reference channel, and 0.05 mM biotin is then added at 10 ⁇ L/min. The flow rate was passed through the chip for 2 min, blocking the remaining binding sites of streptavidin.
  • E. coli bacterial solution inducing expression of heavy or light chain 100 ml of E. coli bacterial solution inducing expression of heavy or light chain was collected, and the cells were washed once with 8000 g of PBS at 10 ° C for 10 min, and then resuspended by vigorous shaking with 5 ml of BugBuster Master Mix Extraction Reagents (Merck). Incubate for 20 min at room temperature, Thereafter, the mixture was centrifuged at 6000 g for 15 min at 4 ° C, and the supernatant was discarded to collect inclusion bodies.
  • the above-mentioned inclusion weight was suspended in 5 ml BugBuster Master Mix, and incubated at room temperature for 5 min; 30 ml of BugBuster diluted 10 times, mixed, centrifuged at 6000 g for 15 min at 4 ° C; the supernatant was discarded, and 30 ml of BugBuster resuspended inclusion body was diluted 10 times.
  • the synthesized short peptide SLLMWITQC (Beijing Saibaisheng Gene Technology Co., Ltd.) was dissolved in DMSO to a concentration of 20 mg/ml.
  • the inclusion bodies of the light and heavy chains were dissolved with 8 M urea, 20 mM Tris pH 8.0, 10 mM DTT, and further denatured by adding 3 M guanidine hydrochloride, 10 mM sodium acetate, 10 mM EDTA before renaturation.
  • the SLLMWITQC peptide was added to the refolding buffer (0.4 M L-arginine, 100 mM Tris pH 8.3, 2 mM EDTA, 0.5 mM oxidized glutathione, 5 mM reduced glutathione, at 25 mg/L (final concentration), 0.2 mM PMSF, cooled to 4 ° C), then add 20 mg / L light chain and 90 mg / L heavy chain (final concentration, heavy chain added three times, 8h / time), renaturation at 4 ° C for at least 3 days By the time of completion, SDS-PAGE can be used to detect renaturation.
  • the refolding buffer 0.4 M L-arginine, 100 mM Tris pH 8.3, 2 mM EDTA, 0.5 mM oxidized glutathione, 5 mM reduced glutathione, at 25 mg/L (final concentration), 0.2 mM PMSF, cooled to 4 ° C
  • the renaturation buffer was replaced with 10 volumes of 20 mM Tris pH 8.0 for dialysis, and at least two buffers were exchanged to substantially reduce the ionic strength of the solution.
  • the protein solution was filtered through a 0.45 ⁇ m cellulose acetate filter and then loaded onto a HiTrap Q HP (GE General Electric Company) anion exchange column (5 ml bed volume).
  • the protein was eluted using a linear gradient of 0-400 mM NaCl prepared by an Akta Purifier (GE General Electric Company), 20 mM Tris pH 8.0, pMHC was eluted at approximately 250 mM NaCl, peak fractions were collected, and purity was determined by SDS-PAGE.
  • the purified pMHC molecule was concentrated using a Millipore ultrafiltration tube while the buffer was replaced with 20 mM Tris pH 8.0, followed by biotinylation reagent 0.05M Bicine pH 8.3, 10 mM ATP, 10 mM MgOAc, 50 ⁇ M D-Biotin, 100 ⁇ g/ml BirA
  • the enzyme (GST-BirA) was incubated overnight at room temperature and SDS-PAGE was used to determine if biotinylation was complete.
  • the biotinylated labeled pMHC molecule was concentrated to 1 ml using a Millipore ultrafiltration tube, biotinylated pMHC was purified by gel filtration chromatography, and HiPrep was pre-equilibrated with filtered PBS using an Akta Purifier (GE General Electric Company).
  • Akta Purifier GE General Electric Company
  • a TM 16/60S200 HR column (GE General Electric Company) was loaded with 1 ml of concentrated biotinylated pMHC molecules and then eluted with PBS at a flow rate of 1 ml/min.
  • the biotinylated pMHC molecule appeared as a single peak elution at about 55 ml.
  • the protein-containing fractions were pooled, concentrated using a Millipore ultrafiltration tube, protein concentration was determined by BCA method (Thermo), and biotinylated pMHC molecules were dispensed at -80 °C by adding protease inhibitor cocktail (Roche).
  • the kinetic parameters of the soluble TCR molecule of the present invention and the soluble single-chain TCR molecule constructed by the present invention in combination with the SLLMWITQC-HLA A0201 complex were calculated using BIAcore Evaluation software, as shown in Figures 12 and 13, respectively.
  • the map shows that the soluble TCR molecule and the soluble single-chain TCR molecule obtained by the present invention are capable of binding to the SLLMWITQC-HLA A0201 complex.
  • the binding activity of the soluble TCR molecule of the present invention and other several unrelated antigenic short peptides to the HLA complex was also detected by the above method, and the results showed that the TCR molecule of the present invention did not bind to other unrelated antigens.
  • Example 7 Killing experiments of cells transducing TCR of the present invention
  • This example measures the release of LDH by a non-radioactive cytotoxicity assay to verify the killing function of cells transducing the TCR of the present invention.
  • the components of the assay were added to the plates in the following order: medium was adjusted to effect cells to 2 ⁇ 10 6 cells/ml, and the medium was adjusted to 5 ⁇ 10 5 cells/ml. After mixing well, 100 ⁇ L of target cell line 5 ⁇ 10 5 cells/ml (ie 50,000 cells/well) and 100 ⁇ L of effector cells 2 ⁇ 10 6 cells/ml (ie 200,000 cells/well) were added to the corresponding wells, and Set up three duplicate holes. At the same time, the spontaneous cells of the effector cells, the spontaneous pores of the target cells, the largest pores of the target cells, the volume corrected control wells and the medium background control wells were set.
  • the cells transducing the TCR of the present invention have a killing effect on target cells expressing the relevant antigen, but have no killing effect on target cells which do not express the relevant antigen.

Abstract

L'invention concerne un récepteur des lymphocytes T (TCR) pouvant se lier spécifiquement à un oligopolypeptide SLLMWITQC dérivé d'antigènes NY-ESO-1. L'oligopeptide SLLMWITQC d'antigènes peut former un composé avec HLA a0201, et le composé est présenté à une surface cellulaire. L'invention concerne également une molécule d'acide nucléique codant pour ledit TCR et un vecteur contenant ladite molécule d'acide nucléique, ainsi qu'une cellule transduisant le TCR.
PCT/CN2016/104453 2015-11-04 2016-11-03 Tcr pour identifier un oligopeptide d'antigènes ny-eso-1 WO2017076308A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510751225 2015-11-04
CN201510751225.5 2015-11-04

Publications (1)

Publication Number Publication Date
WO2017076308A1 true WO2017076308A1 (fr) 2017-05-11

Family

ID=58661724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/104453 WO2017076308A1 (fr) 2015-11-04 2016-11-03 Tcr pour identifier un oligopeptide d'antigènes ny-eso-1

Country Status (2)

Country Link
CN (1) CN106632660B (fr)
WO (1) WO2017076308A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3549954A4 (fr) * 2016-11-29 2020-09-09 Guangdong Xiangxue Life Sciences, Ltd. Tcr à haute affinité pour ny-eso
WO2020263830A1 (fr) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Protéines de fusion flt3l-fc et procédés d'utilisation
WO2021163064A2 (fr) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Anticorps et protéines de fusion se liant à ccr8, et leurs utilisations
EP3687553A4 (fr) * 2017-09-27 2022-01-05 University of Southern California Nouvelles plates-formes pour la co-stimulation, nouvelles conceptions de car et autres améliorations pour une thérapie cellulaire adoptive
WO2022087149A2 (fr) 2020-10-22 2022-04-28 Gilead Sciences, Inc. Protéines de fusion d'interleukine-2-fc et méthodes d'utilisation
WO2022245671A1 (fr) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Méthodes d'utilisation de protéines de fusion flt3l-fc
EP4011909A4 (fr) * 2019-08-02 2023-04-05 XLifeSc, Ltd. Récepteur de slymphocytes t de haute affinité capable d'identifier l'antigène ny-eso-1
WO2023122581A2 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées
WO2023122615A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
EP4245756A1 (fr) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Agents de dégradation de la famille des doigts de zinc de l'ikaros et leurs utilisations
WO2023205719A1 (fr) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Composés modulateurs de kras g12d
WO2024006929A1 (fr) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Composés cd73

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109251244B (zh) * 2017-07-13 2021-10-26 中国科学院广州生物医药与健康研究院 一种识别源自于ebv膜蛋白lmp1抗原的tcr
US20200247851A1 (en) * 2017-08-11 2020-08-06 Tribiotica Llc Methods For Generating Epitopes For Binding To Recognition Molecules By Templated Assembly
CN109836489A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向ny-eso-1的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用
CN111819194A (zh) * 2018-02-26 2020-10-23 基因医疗免疫疗法有限责任公司 Nyeso t细胞受体(tcr)
CN112442118B (zh) * 2019-08-30 2023-02-14 深圳普瑞金生物药业股份有限公司 一种tcr及其应用
CN113880953A (zh) * 2020-07-01 2022-01-04 华夏英泰（北京）生物技术有限公司 T细胞抗原受体、其多聚体复合物及其制备方法和应用
AU2021426928A1 (en) 2021-02-09 2023-09-21 Liyang Tcr Biotherapeutics Co.Ltd Tcr and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031221A1 (fr) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Préparations comprenant des récepteurs cellulaires t et méthodes d'utilisation de ces préparations
CN1989153A (zh) * 2004-05-19 2007-06-27 阿维德克斯有限公司 高亲和力ny－eso t细胞受体
WO2008037943A1 (fr) * 2006-09-29 2008-04-03 Medigene Limited Cellules transformées par un acide nucléique codant pour des récepteurs des lymphocytes t ny-eso
WO2010106431A2 (fr) * 2009-03-20 2010-09-23 Ludwig Institute For Cancer Research Ltd Anticorps anti-peptide ny-eso-1 de type récepteur des cellules t de haute affinité, procédés, et leurs utilisations
WO2014160030A2 (fr) * 2013-03-13 2014-10-02 Health Research, Inc. Compositions et procédés pour l'utilisation de récepteurs de lymphocytes t recombinants pour la reconnaissance directe d'un antigène tumoral
CN104507963A (zh) * 2012-05-22 2015-04-08 美国卫生和人力服务部 鼠抗-ny-eso-1t细胞受体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0524477D0 (en) * 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
PT2016102E (pt) * 2006-05-03 2012-05-15 Us Gov Health & Human Serv Recetores de célula t quimérica e materiais relacionados e métodos de uso
CN101381402B (zh) * 2008-10-20 2011-06-01 中国人民解放军第三军医大学 Ny-eso-1肿瘤抗原模拟表位及其应用
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1989153A (zh) * 2004-05-19 2007-06-27 阿维德克斯有限公司 高亲和力ny－eso t细胞受体
WO2006031221A1 (fr) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Préparations comprenant des récepteurs cellulaires t et méthodes d'utilisation de ces préparations
WO2008037943A1 (fr) * 2006-09-29 2008-04-03 Medigene Limited Cellules transformées par un acide nucléique codant pour des récepteurs des lymphocytes t ny-eso
WO2010106431A2 (fr) * 2009-03-20 2010-09-23 Ludwig Institute For Cancer Research Ltd Anticorps anti-peptide ny-eso-1 de type récepteur des cellules t de haute affinité, procédés, et leurs utilisations
CN104507963A (zh) * 2012-05-22 2015-04-08 美国卫生和人力服务部 鼠抗-ny-eso-1t细胞受体
WO2014160030A2 (fr) * 2013-03-13 2014-10-02 Health Research, Inc. Compositions et procédés pour l'utilisation de récepteurs de lymphocytes t recombinants pour la reconnaissance directe d'un antigène tumoral

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3549954A4 (fr) * 2016-11-29 2020-09-09 Guangdong Xiangxue Life Sciences, Ltd. Tcr à haute affinité pour ny-eso
EP3687553A4 (fr) * 2017-09-27 2022-01-05 University of Southern California Nouvelles plates-formes pour la co-stimulation, nouvelles conceptions de car et autres améliorations pour une thérapie cellulaire adoptive
WO2020263830A1 (fr) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Protéines de fusion flt3l-fc et procédés d'utilisation
EP4011909A4 (fr) * 2019-08-02 2023-04-05 XLifeSc, Ltd. Récepteur de slymphocytes t de haute affinité capable d'identifier l'antigène ny-eso-1
WO2021163064A2 (fr) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Anticorps et protéines de fusion se liant à ccr8, et leurs utilisations
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
WO2022087149A2 (fr) 2020-10-22 2022-04-28 Gilead Sciences, Inc. Protéines de fusion d'interleukine-2-fc et méthodes d'utilisation
WO2022245671A1 (fr) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Méthodes d'utilisation de protéines de fusion flt3l-fc
WO2023122581A2 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées
WO2023122615A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
EP4245756A1 (fr) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Agents de dégradation de la famille des doigts de zinc de l'ikaros et leurs utilisations
WO2023178181A1 (fr) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
WO2023205719A1 (fr) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Composés modulateurs de kras g12d
WO2024006929A1 (fr) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Composés cd73

Also Published As

Publication number Publication date
CN106632660B (zh) 2021-01-29
CN106632660A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
WO2017076308A1 (fr) Tcr pour identifier un oligopeptide d'antigènes ny-eso-1
CN107197625B (zh) 识别ny-eso-1抗原短肽的t细胞受体
EP3858852B1 (fr) Récepteur de lymphocytes t reconnaissant un antigène ssx2
AU2020363138B2 (en) T cell receptor recognising KRAS mutation and encoding sequence thereof
CN106749620B (zh) 识别mage-a1抗原短肽的t细胞受体
CN106831978B (zh) 识别prame抗原的t细胞受体
WO2020024915A1 (fr) Récepteur de lymphocytes t pour identifier un antigène afp
CN106632658B (zh) 识别ny-eso-1抗原短肽的tcr
WO2021022447A1 (fr) Récepteur de slymphocytes t capable de reconnaître un peptide court dérivé d'un antigène afp
WO2021016887A1 (fr) Récepteur de lymphocytes t reconnaissant le peptide court de l'antigène ssx2
WO2016177195A1 (fr) Récepteur des cellules t permettant de reconnaître le polypeptide à chaîne courte de l'antigène rhamm
WO2021170117A1 (fr) Récepteur de lymphocytes t reconnaissant un peptide court d'antigène afp et séquence de codage de celui-ci
WO2021170116A1 (fr) Récepteur de lymphocytes t reconnaissant l'afp
CN108264550B (zh) 一种识别源自于prame抗原短肽的tcr
CN109251243B (zh) 一种识别sage1抗原的t细胞受体及编码该受体的核酸
WO2021139699A1 (fr) Récepteur de lymphocytes t pour la reconnaissance de l'afp et séquence codante associée
CN108929378B (zh) 一种识别prame抗原的t细胞受体及编码该受体的核酸
CN109890839B (zh) 识别sage1抗原短肽的t细胞受体
CN108659114B (zh) 识别pasd1抗原短肽的tcr
WO2022206861A1 (fr) Récepteur de lymphocytes t pour l'identification d'afp
WO2022262835A1 (fr) Tcr pour identifier un antigène afp et séquence codant pour celui-ci
WO2022166904A1 (fr) Récepteur de lymphocytes t pour identifier l'hpv
WO2023241391A1 (fr) Molécule de tcr se liant à un antigène ssx2 et son utilisation
CN110272483B (zh) 识别sage1抗原短肽的t细胞受体
WO2021035446A1 (fr) Récepteur de lymphocytes t pour la reconnaissance d'un peptide court d'antigène afp et séquence de codage de celui-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16861576

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16861576

Country of ref document: EP

Kind code of ref document: A1